Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05494541 · ClinicalTrials.gov registry record
Characteristics of Patients With Sickle Cell Disease
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 540
- Enrollment target
NCT05494541 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 540 participants.
The verdict
NCT05494541 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 540 participants
- Enrollment target
Study Summary
This was a retrospective descriptive analysis of health care claims data using the IQVIA open source medical and pharmacy claims databases.
Interventions
- OTHER Crizanlizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2021-08-30 |
| Est. Completion | 2021-10-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05494541
The ClinicalTrials.gov registry entry for NCT05494541 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 540 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Crizanlizumab is the first listed.
NCT05494541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05494541 about?
NCT05494541 is a clinical study titled "Characteristics of Patients With Sickle Cell Disease". This was a retrospective descriptive analysis of health care claims data using the IQVIA open source medical and pharmacy claims databases.
What is the current status of trial NCT05494541?
This trial is currently completed. The enrollment target is 540 participants. The study started on 2021-08-30. Estimated completion is 2021-10-27.
What interventions are being tested in trial NCT05494541?
The interventions under investigation include: Crizanlizumab (OTHER).
Who is sponsoring clinical trial NCT05494541?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.